<DOC>
	<DOCNO>NCT00604214</DOCNO>
	<brief_summary>The purpose placebo-controlled study determine drotrecogin alfa ( activate ) treatment provide significant mortality reduction improvement patient septic shock compare placebo treatment patient receive current standard care septic shock . This study also assess effectiveness drotrecogin alfa ( activate ) reduce 28-day mortality patient septic shock concomitant severe protein C deficiency .</brief_summary>
	<brief_title>Efficacy Safety Drotrecogin Alfa ( Activated ) Adult Patients With Septic Shock</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Must 18 year old Must evidence infection Must systemic inflammatory response syndrome ( SIRS ) Must vasopressordependent septic shock Have receive vasopressor therapy ( dose ) great 24 hour prior start study drug Have sepsisinduced organ dysfunction great 36 hour prior start study drug infusion Have single organ dysfunction recent surgery ( within 30 day study entry ) Have surgery perform within 12hour period immediately precede study drug infusion , postoperative evidence active bleeding , plan anticipate surgery infusion period Are expect survive 28 day give preexist uncorrectable medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Sepsis</keyword>
	<keyword>Septic shock</keyword>
</DOC>